Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022 October 19, 2022October 19, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Roche to present new data on OCREVUS in multiple…Data up to 8-years for Roche’s OCREVUS (ocrelizumab)…New four-year data show Roche's ENSPRYNG…Roche’s ENSPRYNG approved by European Commission as…New data for Roche’s OCREVUS (ocrelizumab) show…Data at the 2022 ASCO Annual Meeting highlight…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
